RTS Radio Interview with Dr. Julien Déglon
RTS Interview with our Co-Founder & CTO Dr. Julien D…
Tech Tour announces the top 20 Medtech companies in Europe
Geneva and Brussels, June 30th, 2015 - The Tech Tour today announced…
300’000 CHF pour le développement de DBS System
DBS System a obtenu un prêt Early de 300’000 CHF de la Fondation…
Deux prêts de la FIT attribués à deux start-up vaudoises
DBS System a obtenu un prêt early de 300.000 francs et Cellestia…
Grant of a FIT early loan of CHF 300’000
DBS Systema obtenuunprêt Early de 300’000francsde la Fondation…
Les tests sanguins à portée de main
Pourquoi prélever 10 mL de sang, quand on peut faire une analyse…
La FIT soutient deux entreprises dans le domaine des sciences de la vie
DBS System a obtenu un prêt Early de 300’000 francs. L’entreprise…
DISCLAIMER
HemaXis DB is a FDA Class 1 medical device. HemaXis DX is in development and for research purposes only. Use of HemaXis devices in Laboratory Developed Tests (LDTs) requires further processing including the establishment of performance characteristics and successful validation by the laboratory in a manner consistent with local regulatory requirements.
By using this website you are agreeing to our Terms and Conditions.
CONTACT
DBS System SA
Rte des Avouillons 6
CH-1196 Gland
Switzerland
Tel: +41 (0) 78 624 70 15
Email: info@dbs-system.ch
LEGAL DOCUMENTS
Read Our Privacy Policy
Read Our General Terms and Conditions of Sale
Read Our Shipping Information